290650

L&C BIO is a biotechnology company that manufactures and sells human tissue grafts, tissue-based medical devices, cosmeceuticals, and pharmaceuticals. The company's primary revenue is generated from human tissue grafts, which include products for bone, cartilage, fascia, skin, amnion, ligaments, tendons, heart valves, blood vessels, nerves, and pericardium. Its flagship product, MegaDerm, is an acellular dermal matrix used for breast reconstruction following cancer treatment. L&C BIO also develops tissue-based medical devices by cross-linking human tissue with biopolymers, targeting markets in China, Southeast Asia, Latin America, and the Middle East where tissue laws are less established. The company operates in the cosmeceutical sector, producing functional cosmetics and health functional foods, and provides Contract Research Organization (CRO) services for cosmetic and pharmaceutical testing through its subsidiary Global Medical Research Center. Additionally, L&C BIO engages in pharmaceutical business activities utilizing its existing surgical network. Key products under development include MegaCarti for osteoarthritis, MegaShield as an anti-adhesion barrier, and MegaNerve Prime for nerve grafting. The company serves domestic hospitals, clinics, and burn centers in South Korea, while expanding internationally through local partners and academic collaborations. Subsidiaries include L&C Medical, L&C Care, and L&C China, which support its operations in medical device distribution, healthcare services, and the Chinese market.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Medical Devices Homepage lncbio.co.kr
Sector Healthcare IR page —
Tags
human tissue grafts, acellular dermal matrix, regenerative medicine, cosmeceuticals, cosmetic cro, pharmaceuticals, biopolymers, nerve grafts, anti-adhesion barriers, breast reconstruction, MegaDerm, MegaCarti, MegaShield, MegaNerve Prime, MegaDBM S, MegaCure, MegaAdipo ECM, Mega3DEar, MegaCartilage-E, MegaCare W, ZAG peptide, MegaPlug, MegaFill Putty, TendonFill, Sheet type MegaFill, MegaDerm Soft FD type, Pocket type ADM, ES.Fill, ES.Stat, Re2O, BytheDoctor Ato, MF3, Global Medical Research Center, L&C Medical, L&C Care, L&C China
Press page —

Metrics

Valuation  
Market cap ₩ 2.605T
Market cap (USD) $ 1.917B
P/E -17.30
PEG —
P/BV 8.02
P/S 22.42
P/OCF 99.79
P/FCF -672.25
Dividend yield —
Turnover / mcap —
Returns  
ROE -57.3%
ROI -69.7%
ROIC 1.7%
Profit margin -161.7%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock —
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score -43.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Revenue 85.476B 72.093B 68.87B 52.572B 45.677B 32.973B 29.152B 21.241B 17.901B 11.822B
Net profit -138.175B 141.064B 48.361B 4.544B 13.814B 10.813B 7.25B 5.208B 3.753B 1.981B
Free cash flow -3.245B -13.282B -36.636B -43.607B 655.691M 4.403B 4.473B -893.381M 3.533B -816.262M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Share price 53.838K — — — — — — — — —
P/FCF -408.42 — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 4.35B 6.01B 7.5B 10.1B 9.33B 14.8B 16.8B 22.6B 54.2B 25.7B
↳ YoY growth +38.0% +24.8% +35.3% -8.0% +58.8% +13.3% +34.8% +139.4% -52.5%
↳ 5y CAGR +27.8% +22.8% +24.7% +39.8% +22.5%
Borrowings, current (KRW) 542M 463M 0.00 — — 126M 9.67B 72.2B 98.1B 48.5B
Borrowings, non-current (KRW) 401M 0.00 1B 1B 9.62B 5.45B 59.8B 541M 20.1B 4.02B
Bonds payable (KRW) — — — — 8.62B 4.57B 59.1B 63.8B 66.4B 48.5B
Cash and deposits (KRW) 383M 3.12B 21.6B 12.8B 22.3B 17.4B 6.59B 14.9B 18.3B 30.9B
Intangible assets (KRW) 109M 92.8M 86.6M 218M 215M 1.15B 3.58B 1.46B 199B 128B
Net debt (borrowings + leases - cash) (KRW) 560M -2.66B -20.6B -11.8B -12.6B -11.8B 62.9B 57.8B 99.9B 21.7B
Cash flow detail
Operating cash flow (KRW) -185M 3.82B 3.85B 6.43B 7.42B 10.9B -6.08B -12.1B -8.57B 12.6B
Purchases of property, plant and equipment (KRW) -631M -285M -4.74B -1.96B -3.02B -10.3B -37.5B -24.5B -4.72B -15.8B
Purchases of intangible assets (KRW) -84.9M -13.4M -28.7M -51.5M -38.5M -1.18B -172M -481M -634M -1.23B
Dividends paid (cash effect) (KRW) — — — — -729M -1.08B -1.11B -1.11B -2.27B -1.12B
Share buybacks (cash effect) (KRW) — — — — -12.7B -2.05B — -840M 0.00 -10B
Interest paid (cash effect) (KRW) -43.8M -18.2M -17.5M -16.4M -15.1M -23M -159M -531M -498M -1.86B
Income taxes paid (cash effect) (KRW) -59.9M -505M -1.05B -1.32B -1.59B 514M -1.25B -1.22B -14.9B 283M
Free cash flow (OCF - PPE - intangibles) (KRW) -901M 3.52B -922M 4.42B 4.36B -521M -43.8B -37.1B -13.9B -4.47B
Income detail
Total comprehensive income (KRW) 2.02B 3.89B 5.1B 8.3B 11.9B 16.6B 6.97B 46.1B 139B -138B
Comprehensive income to owners (KRW) 2.02B 3.89B 5.21B 7.1B 10.6B 14.8B 5.8B 46B 139B -138B
Reported Apr 1, 2019 Apr 1, 2019 Apr 1, 2019 Mar 30, 2020 Mar 31, 2021 Mar 20, 2024 Mar 20, 2024 Mar 20, 2024 Mar 24, 2026 Mar 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

기업설명회(IR)개최 Bull 0 Bear 0 Routine

Prompts

L&C BIO (ticker 290650), listed in South Korea.

ETFs Holding L&C BIO

ETF Weight in ETF Shares Market value As of
DEXC 0.01% 1,210 $ 19.508K Nov 12, 2026
DFEM 0.00% 17,253 $ 278.159K Nov 12, 2026
DFAE 0.00% 15,651 $ 252.331K Nov 12, 2026
DFAX 0.00% 6,087 $ 98.137K Nov 12, 2026
DFSE 0.00% 32 $ 515.92 Nov 12, 2026